11 responses to “Tailoring therapy for type 2 diabetes: the role of incretins”

  1. As with all new therapies, this has raised an interesting perspective…I would require my own lit search and more information, as well as an acknowledgement about cost, which is a very real concern to patients who don’t have drug plans (still left bereft by the Canadian Health Care system re pharmaceuticals)

  2. Unfortunately, the new injectable agents are expensive and not available to many people who would benefit from them.

  3. very good summary. learning re : improving A1c targets for type 2 diabetes

  4. Like glitazones, we don’t know long term side effects of this new therapy. They appear promising. High cost is significant barrier as well

  5. It seems to me and I believe the patients, the hardest step is moving is to injectable therapy, be it insulin or the new injectables. The time and effort, supplies, increased testing, hypoglycemia are all significant. I’m not clear that the new injectables are really better than insulin particularly considering the cost.

  6. As my practice as a FP for 40 years is mostly geriatric. There is a rapid increase in this diagnosis noted.
    For THEM….Cost is a major issue.
    For ME……..I will await reports of any serious side effects. I will begin slowly and carefully with this new medicine.

  7. Good summary for one who is not used to be the primary care physician for diabetics

  8. Like others, the cost is the main issue with using the incretins at present. I appreciate the overview of the options available to date

  9. The incretins are an add on therapy, increasing the pill burden. I would need to see data that supports a sustained decrease in the A1C(>2 yrs) before I would consider an incretin over other second line options or consider a change to insulin.

  10. Incretins are an expensive add-on therapy.
    I would need to see data that supports a sustained reduction of the A1C(> 2 yrs) before I would consider an incretin over other second line agents.

  11. I am slowly introducing incretins as well victoza depending on patients extended coverage, and pt’s ability to pay for these expensive medications. The general response has been positive and it’s a shame that these meds are not available universally.
    In my practice, weight loss is not a given with victoza but it does reduce HgA1c.

Leave a Reply